Robert Belshe

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Living Beings

Disorders

Human Influenza

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Damon Inger K; Davidson Whitni B; Hughes Christine M; Olson Victoria A; Smith Scott K; Holman Robert C; Frey Sharon E; Newman Frances; Belshe Robert B; Yan Lihan; Karem Kevin
Evaluation of smallpox vaccines using variola neutralization.
Belshe Robert B
Implications of the emergence of a novel H1 influenza virus.
Triana-Baltzer Gallen B; Gubareva Larisa V; Klimov Alexander I; Wurtman David F; Moss Ronald B; Hedlund Maria; Larson Jeffrey L; Belshe Robert B; Fang Fang
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Robert Belshe (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Damon Inger K; Davidson Whitni B; Hughes Christine M; Olson Victoria A; Smith Scott K; Holman Robert C; Frey Sharon E; Newman Frances; Belshe Robert B; Yan Lihan; Karem Kevin
Evaluation of smallpox vaccines using variola neutralization.
The Journal of general virology 2009;90(Pt 8):1962-6.
2009: Belshe Robert B
Implications of the emergence of a novel H1 influenza virus.
The New England journal of medicine 2009;360(25):2667-8.
2009: Triana-Baltzer Gallen B; Gubareva Larisa V; Klimov Alexander I; Wurtman David F; Moss Ronald B; Hedlund Maria; Larson Jeffrey L; Belshe Robert B; Fang Fang
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.
PloS one 2009;4(11):e7838.
2008: Belshe Robert B
An introduction to influenza: lessons from the past in epidemiology, prevention, and treatment.
Managed care (Langhorne, Pa.) 2008;17(10 Suppl 10):2-7.
2008: Belshe Robert B; Ambrose Christopher S; Yi Tingting
Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.
Vaccine 2008;26 Suppl 4():D10-6.
2008: Luce Bryan R; Nichol Kristin L; Belshe Robert B; Frick Kevin D; Li Su Xia; Boscoe Audra; Rousculp Matthew D; Mahadevia Parthiv J
Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Vaccine 2008;26(23):2841-8.
2008: Bernstein David I; Edwards Kathryn M; Dekker Cornelia L; Belshe Robert; Talbot Helen K B; Graham Irene L; Noah Diana L; He Fenhua; Hill Heather
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
The Journal of infectious diseases 2008;197(5):667-75.
2007: Frey Sharon E; Newman Frances K; Kennedy Jeffrey S; Sobek Vera; Ennis Francis A; Hill Heather; Yan Lihan K; Chaplin Paul; Vollmar Jens; Chaitman Bernard R; Belshe Robert B
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.
Vaccine 2007;25(51):8562-73.
2007: Belshe R B
Translational research on vaccines: influenza as an example.
Clinical pharmacology and therapeutics 2007;82(6):745-9.
2007: Couch Robert B; Winokur Patricia; Brady Rebecca; Belshe Robert; Chen Wilbur H; Cate Thomas R; Sigurdardottir Bryndis; Hoeper Amy; Graham Irene L; Edelman Robert; He Fenhua; Nino Diane; Capellan Jose; Ruben Frederick L
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.
Vaccine 2007;25(44):7656-63.
2007: Wright Peter F; Karron Ruth A; Belshe Robert B; Shi Jian R; Randolph Valerie B; Collins Peter L; O'Shea Alice F; Gruber William C; Murphy Brian R
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
Vaccine 2007;25(42):7372-8.
2007: Belshe Robert B; Newman Frances K; Wilkins Ken; Graham Irene L; Babusis Elizabeth; Ewell Marian; Frey Sharon E
Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults.
Vaccine 2007;25(37-38):6755-63.
2007: Belshe Robert B
The burden of influenza and strategies for prevention.
Managed care (Langhorne, Pa.) 2007;16(8 Suppl 8):2-6; discussion 17-9.
2007: Lawrence Steven J; Lottenbach Kathleen R; Newman Frances K; Buller R Mark L; Bellone Clifford J; Chen John J; Cohen Gary H; Eisenberg Roselyn J; Belshe Robert B; Stanley Samuel L; Frey Sharon E
Antibody responses to vaccinia membrane proteins after smallpox vaccination.
The Journal of infectious diseases 2007;196(2):220-9.
2007: Stanley Samuel L; Frey Sharon E; Taillon-Miller Patricia; Guo Jianhua; Miller Raymond D; Koboldt Daniel C; Elashoff Michael; Christensen Ryan; Saccone Nancy L; Belshe Robert B
The immunogenetics of smallpox vaccination.
The Journal of infectious diseases 2007;196(2):212-9.
2007: Wright Peter F; Deatly Anne M; Karron Ruth A; Belshe Robert B; Shi Jian R; Gruber William C; Zhu Yuwei; Randolph Valerie B
Comparison of results of detection of rhinovirus by PCR and viral culture in human nasal wash specimens from subjects with and without clinical symptoms of respiratory illness.
Journal of clinical microbiology 2007;45(7):2126-9.
2007: van Duin David; Allore Heather G; Mohanty Subhasis; Ginter Sandra; Newman Frances K; Belshe Robert B; Medzhitov Ruslan; Shaw Albert C
Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults.
The Journal of infectious diseases 2007;195(11):1590-7.
2007: Belshe Robert B; Edwards Kathryn M; Vesikari Timo; Black Steven V; Walker Robert E; Hultquist Micki; Kemble George; Connor Edward M;
Live attenuated versus inactivated influenza vaccine in infants and young children.
The New England journal of medicine 2007;356(7):685-96.
2006: Laassri Majid; Lottenbach Kathleen; Belshe Robert; Rennels Margaret; Plotkin Stanley; Chumakov Konstantin
Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
The Journal of infectious diseases 2006;193(10):1344-9.
2006: Madhi Shabir A; Cutland Clare; Zhu Yuwei; Hackell Jill G; Newman Frances; Blackburn Nigel; Murphy Brian R; Belshe Robert B; Karron Ruth A; Deatly Anne M; Gruber William C; Bernstein David I; Wright Peter F
Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.
Vaccine 2006;24(13):2432-9.
2005: Laassri Majid; Lottenbach Kathleen; Belshe Robert; Wolff Mark; Rennels Margaret; Plotkin Stanley; Chumakov Konstantin
Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains.
The Journal of infectious diseases 2005;192(12):2092-8.
2005: Belshe Robert B
The origins of pandemic influenza--lessons from the 1918 virus.
The New England journal of medicine 2005;353(21):2209-11.
2005: Abate Getahun; Eslick Joy; Newman Frances K; Frey Sharon E; Belshe Robert B; Monath Thomas P; Hoft Daniel F
Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions.
The Journal of infectious diseases 2005;192(8):1362-71.
2005: Laassri Majid; Dragunsky Eugenia; Enterline Joan; Eremeeva Tatiana; Ivanova Olga; Lottenbach Kathleen; Belshe Robert; Chumakov Konstantin
Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization.
Journal of clinical microbiology 2005;43(6):2886-94.
2005: Karron Ruth A; Wright Peter F; Belshe Robert B; Thumar Bhagvanji; Casey Roberta; Newman Frances; Polack Fernando P; Randolph Valerie B; Deatly Anne; Hackell Jill; Gruber William; Murphy Brian R; Collins Peter L
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
The Journal of infectious diseases 2005;191(7):1093-104.
2005: Betts Michael R; Exley Barbara; Price David A; Bansal Anju; Camacho Zenaido Tres; Teaberry Vanessa; West Sadie M; Ambrozak David R; Tomaras Georgia; Roederer Mario; Kilby J Michael; Tartaglia Jim; Belshe Robert; Gao Feng; Douek Daniel C; Weinhold Kent J; Koup Richard A; Goepfert Paul; Ferrari Guido
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(12):4512-7.
2004: Belshe Robert; Lee Min-Shi; Walker Robert E; Stoddard Jeffrey; Mendelman Paul M
Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.
Expert review of vaccines 2004;3(6):643-54.
2004: Hoft Daniel F; Belshe Robert B
The genetic archaeology of influenza.
The New England journal of medicine 2004;351(24):2550-1.
2004: Belshe Robert B; Newman Frances K; Anderson Edwin L; Wright Peter F; Karron Ruth A; Tollefson Sharon; Henderson Frederick W; Meissner H Cody; Madhi Shabir; Roberton Don; Marshall Helen; Loh Richard; Sly Peter; Murphy Brian; Tatem Joanne M; Randolph Valerie; Hackell Jill; Gruber William; Tsai Theodore F
Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
The Journal of infectious diseases 2004;190(12):2096-103.
2004: Belshe Robert B; Newman Frances K; Cannon Joan; Duane Carol; Treanor John; Van Hoecke Christian; Howe Barbara J; Dubin Gary
Serum antibody responses after intradermal vaccination against influenza.
The New England journal of medicine 2004;351(22):2286-94.
2004: Belshe Robert B; Nichol Kristin L; Black Steven B; Shinefield Henry; Cordova Julie; Walker Robert; Hessel Colin; Cho Iksung; Mendelman Paul M
Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(7):920-7.
2004: Kennedy Jeffrey S; Frey Sharon E; Yan Lihan; Rothman Alan L; Cruz John; Newman Frances K; Orphin Laura; Belshe Robert B; Ennis Francis A
Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination.
The Journal of infectious diseases 2004;190(7):1286-94.
2004: Lee Deborah; Graham Barney S; Chiu Ya-Lin; Gilbert Peter B; McElrath M Juliana; Belshe Robert B; Buchbinder Susan P; Sheppard Haynes W; Koblin Beryl A; Mayer Kenneth H; Keefer Michael C; Mulligan Mark J; Celum Connie L
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
The Journal of infectious diseases 2004;190(5):903-7.
2004: Belshe Robert; Franchini Genoveffa; Girard Marc P; Gotch Frances; Kaleebu Pontiano; Marthas Marta L; McChesney Michael B; McCullough Rose; Mhalu Fred; Salmon-Ceron Dominique; Sekaly Rafick-Pierre; van Rompay Koen; Verrier Bernard; Wahren Britta; Weissenbacher Mercedes
Support for the RV144 HIV vaccine trial.
Science (New York, N.Y.) 2004;305(5681):177-80; author reply 177-80.
2004: Belshe Robert B
Current status of live attenuated influenza virus vaccine in the US.
Virus research 2004;103(1-2):177-85.
2004: Zangwill Kenneth M; Belshe Robert B
Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination.
The Pediatric infectious disease journal 2004;23(3):189-97.
2004: Belshe Robert B; Newman Frances K; Frey Sharon E; Couch Robert B; Treanor John J; Tacket Carol O; Yan Lihan
Dose-dependent neutralizing-antibody responses to vaccinia.
The Journal of infectious diseases 2004;189(3):493-7.
2004: Belshe Robert B; Newman Frances K; Tsai Theodore F; Karron Ruth A; Reisinger Keith; Roberton Don; Marshall Helen; Schwartz Richard; King James; Henderson Frederick W; Rodriguez William; Severs Joseph M; Wright Peter F; Keyserling Harry; Weinberg Geoffrey A; Bromberg Kenneth; Loh Richard; Sly Peter; McIntyre Peter; Ziegler John B; Hackell Jill; Deatly Anne; Georgiu Alice; Paschalis Maribel; Wu Shin-Lu; Tatem Joanne M; Murphy Brian; Anderson Edwin
Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
The Journal of infectious diseases 2004;189(3):462-70.
2004: Hayden Frederick G; Belshe Robert; Villanueva Catalina; Lanno Riin; Hughes Claire; Small Ian; Dutkowski Regina; Ward Penelope; Carr Jackie
Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.
The Journal of infectious diseases 2004;189(3):440-9.
2004: Frey Sharon E; Belshe Robert B
Poxvirus zoonoses--putting pocks into context.
The New England journal of medicine 2004;350(4):324-7.
2004: Gorse Geoffrey J; Patel Gira B; Arbuckle J Alan; Belshe Robert B
Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection.
Vaccine 2004;22(3-4):383-97.
2003: Belshe Robert B; Mendelman Paul M
Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent.
Immunology and allergy clinics of North America 2003;23(4):745-67.
2003: Newman Frances K; Frey Sharon E; Blevins Tamara P; Mandava Mahendra; Bonifacio Andres; Yan Lihan; Belshe Robert B
Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine.
Journal of clinical microbiology 2003;41(7):3154-7.
2003: Frey Sharon E; Newman Frances K; Yan Lihan; Lottenbach Kathleen R; Belshe Robert B
Response to smallpox vaccine in persons immunized in the distant past.
JAMA : the journal of the American Medical Association 2003;289(24):3295-9.
2003: Karron Ruth A; Belshe Robert B; Wright Peter F; Thumar Bhagvanji; Burns Barbars; Newman Frances; Cannon Joan C; Thompson Juliette; Tsai Theodore; Paschalis Maribel; Wu Shin-Lu; Mitcho Yvonne; Hackell Jill; Murphy Brian R; Tatem Joanna M
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
The Pediatric infectious disease journal 2003;22(5):394-405.
2003: Newman Frances K; Frey Sharon E; Blevins Tamara P; Yan Lihan; Belshe Robert B
Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax.
The Journal of infectious diseases 2003;187(8):1319-22.
2003: Bernstein David I; Yan Lihan; Treanor John; Mendelman Paul M; Belshe Robert;
Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children.
The Pediatric infectious disease journal 2003;22(1):28-34.
2002: Piedra Pedro A; Yan Lihan; Kotloff Karen; Zangwill Ken; Bernstein David I; King James; Treanor John; Munoz Flor; Wolff Mark; Cho Iksung; Mendelman Paul M; Cordova Julie; Belshe Robert B
Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children.
Pediatrics 2002;110(4):662-72.
2002: Belshe Robert B; Couch Robert B; Glezen William P; Treanor John T
Live attenuated intranasal influenza vaccine.
Vaccine 2002;20(29-30):3429-30.
2002: Frey Sharon E; Couch Robert B; Tacket Carol O; Treanor John J; Wolff Mark; Newman Frances K; Atmar Robert L; Edelman Robert; Nolan Carrie M; Belshe Robert B;
Clinical responses to undiluted and diluted smallpox vaccine.
The New England journal of medicine 2002;346(17):1265-74.
2002: Frey Sharon E; Newman Frances K; Cruz John; Shelton W Brian; Tennant Janice M; Polach Tamara; Rothman Alan L; Kennedy Jeffrey S; Wolff Mark; Belshe Robert B; Ennis Francis A
Dose-related effects of smallpox vaccine.
The New England journal of medicine 2002;346(17):1275-80.
2002: Treanor John; Keitel Wendy; Belshe Robert; Campbell James; Schiff Gilbert; Zangwill Ken; Wolff Mark; Klimov Alexander; Levandowski Roland; Lambert Linda
Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults.
Vaccine 2002;20(7-8):1099-105.
2001: Belshe R B; Gruber W C
Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
Philosophical transactions of the Royal Society of London. Series B, Biological sciences 2001;356(1416):1947-51.
2001: King J C; Fast P E; Zangwill K M; Weinberg G A; Wolff M; Yan L; Newman F; Belshe R B; Kovacs A; Deville J G; Jelonek M;
Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
The Pediatric infectious disease journal 2001;20(12):1124-31.
2001: Worku S; Gorse G J; Belshe R B; Hoft D F
Canarypox vaccines induce antigen-specific human gammadelta T cells capable of interferon-gamma production.
The Journal of infectious diseases 2001;184(5):525-32.
2001: Gorse G J; Patel G B; Belshe R B;
HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.
AIDS research and human retroviruses 2001;17(12):1175-89.
2001: Luce B R; Zangwill K M; Palmer C S; Mendelman P M; Yan L; Wolff M C; Cho I; Marcy S M; Iacuzio D; Belshe R B
Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children.
Pediatrics 2001;108(2):E24.
2001: Ray R; Hoft D F; Meyer K; Brown R; Lagging L M; Belshe R B
Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus.
Virus research 2001;75(2):147-54.
2001: Belshe R B; Stevens C; Gorse G J; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler J L; Klein M; Habib R E; Duliege A M; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
The Journal of infectious diseases 2001;183(9):1343-52.
2001: Evans T G; McElrath M J; Matthews T; Montefiori D; Weinhold K; Wolff M; Keefer M C; Kallas E G; Corey L; Gorse G J; Belshe R; Graham B S; Spearman P W; Schwartz D; Mulligan M J; Goepfert P; Fast P; Berman P; Powell M; Francis D;
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
Vaccine 2001;19(15-16):2080-91.
2001: Gorse G J; Patel G B; Mandava M D; Arbuckle J A; Doyle T M; Belshe R B;
Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.
Vaccine 2001;19(13-14):1806-19.
2000: Verrier F; Burda S; Belshe R; Duliege A M; Excler J L; Klein M; Zolla-Pazner S
A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
Journal of virology 2000;74(21):10025-33.
2000: Wright P F; Karron R A; Belshe R B; Thompson J; Crowe J E; Boyce T G; Halburnt L L; Reed G W; Whitehead S S; Anderson E L; Wittek A E; Casey R; Eichelberger M; Thumar B; Randolph V B; Udem S A; Chanock R M; Murphy B R
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
The Journal of infectious diseases 2000;182(5):1331-42.
2000: Sabbaj S; Mulligan M J; Hsieh R H; Belshe R B; McGhee J R
Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group.
AIDS (London, England) 2000;14(10):1365-74.
2000: Hoft D F; Brown R M; Belshe R B
Mucosal bacille calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;30 Suppl 3():S217-22.
2000: McElrath M J; Corey L; Montefiori D; Wolff M; Schwartz D; Keefer M; Belshe R; Graham B S; Matthews T; Wright P; Gorse G; Dolin R; Berman P; Francis D; Duliege A M; Bolognesi D; Stablein D; Ketter N; Fast P
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 2000;16(9):907-19.
2000: Belshe R B; Gruber W C
Prevention of otitis media in children with live attenuated influenza vaccine given intranasally.
The Pediatric infectious disease journal 2000;19(5 Suppl):S66-71.
2000: Belshe R B; Gruber W C; Mendelman P M; Mehta H B; Mahmood K; Reisinger K; Treanor J; Zangwill K; Hayden F G; Bernstein D I; Kotloff K; King J; Piedra P A; Block S L; Yan L; Wolff M
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
The Journal of infectious diseases 2000;181(3):1133-7.
2000: Longini I M; Halloran M E; Nizam A; Wolff M; Mendelman P M; Fast P E; Belshe R B
Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control.
Vaccine 2000;18(18):1902-9.
2000: King J C; Treanor J; Fast P E; Wolff M; Yan L; Iacuzio D; Readmond B; O'Brien D; Mallon K; Highsmith W E; Lambert J S; Belshe R B
Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.
The Journal of infectious diseases 2000;181(2):725-8.
2000: Belshe R B; Gruber W C; Mendelman P M; Cho I; Reisinger K; Block S L; Wittes J; Iacuzio D; Piedra P; Treanor J; King J; Kotloff K; Bernstein D I; Hayden F G; Zangwill K; Yan L; Wolff M
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
The Journal of pediatrics 2000;136(2):168-75.
1999: Treanor J J; Kotloff K; Betts R F; Belshe R; Newman F; Iacuzio D; Wittes J; Bryant M
Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.
Vaccine 1999;18(9-10):899-906.
1999: Gorse G J; Patel G B; Mandava M D; Belshe R B
Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies.
Vaccine 1999;18(9-10):835-49.
1999: Hoft D F; Kemp E B; Marinaro M; Cruz O; Kiyono H; McGhee J R; Belisle J T; Milligan T W; Miller J P; Belshe R B
A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination.
The Journal of laboratory and clinical medicine 1999;134(3):244-52.
1999: Nichol K L; Mendelman P M; Mallon K P; Jackson L A; Gorse G J; Belshe R B; Glezen W P; Wittes J
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.
JAMA : the journal of the American Medical Association 1999;282(2):137-44.
1999: Gorse G J; Patel G B; Mandava M; Berman P W; Belshe R B
MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
AIDS research and human retroviruses 1999;15(10):921-30.
1999: Gorse G J; Corey L; Patel G B; Mandava M; Hsieh R H; Matthews T J; Walker M C; McElrath M J; Berman P W; Eibl M M; Belshe R B
HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 1999;15(2):115-32.
1998: Belshe R B; Gorse G J; Mulligan M J; Evans T G; Keefer M C; Excler J L; Duliege A M; Tartaglia J; Cox W I; McNamara J; Hwang K L; Bradney A; Montefiori D; Weinhold K J
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
AIDS (London, England) 1998;12(18):2407-15.
1998: Francis D P; Gregory T; McElrath M J; Belshe R B; Gorse G J; Migasena S; Kitayaporn D; Pitisuttitham P; Matthews T; Schwartz D H; Berman P W
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
AIDS research and human retroviruses 1998;14 Suppl 3():S325-31.
1998: Granoff D M; Gupta R K; Belshe R B; Anderson E L
Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.
The Journal of infectious diseases 1998;178(3):870-4.
1998: King J C; Lagos R; Bernstein D I; Piedra P A; Kotloff K; Bryant M; Cho I; Belshe R B
Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children.
The Journal of infectious diseases 1998;177(5):1394-7.
1998: Clements-Mann M L; Weinhold K; Matthews T J; Graham B S; Gorse G J; Keefer M C; McElrath M J; Hsieh R H; Mestecky J; Zolla-Pazner S; Mascola J; Schwartz D; Siliciano R; Corey L; Wright P F; Belshe R; Dolin R; Jackson S; Xu S; Fast P; Walker M C; Stablein D; Excler J L; Tartaglia J; Paoletti E
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1998;177(5):1230-46.
1998: Belshe R B; Mendelman P M; Treanor J; King J; Gruber W C; Piedra P; Bernstein D I; Hayden F G; Kotloff K; Zangwill K; Iacuzio D; Wolff M
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
The New England journal of medicine 1998;338(20):1405-12.
1998: Gorse G J; McElrath M J; Matthews T J; Hsieh R H; Belshe R B; Corey L; Frey S E; Kennedy D J; Walker M C; Eibl M M
Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Vaccine 1998;16(5):493-506.
1998: Belshe R B
Influenza as a zoonosis: how likely is a pandemic?
Lancet 1998;351(9101):460-1.
1998: Graham B S; McElrath M J; Connor R I; Schwartz D H; Gorse G J; Keefer M C; Mulligan M J; Matthews T J; Wolinsky S M; Montefiori D C; Vermund S H; Lambert J S; Corey L; Belshe R B; Dolin R; Wright P F; Korber B T; Wolff M C; Fast P E
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
The Journal of infectious diseases 1998;177(2):310-9.
1997: Keefer M C; Wolff M; Gorse G J; Graham B S; Corey L; Clements-Mann M L; Verani-Ketter N; Erb S; Smith C M; Belshe R B; Wagner L J; McElrath M J; Schwartz D H; Fast P
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 1997;13(14):1163-77.
1997: Zolla-Pazner S; Alving C; Belshe R; Berman P; Burda S; Chigurupati P; Clements M L; Duliege A M; Excler J L; Hioe C; Kahn J; McElrath M J; Sharpe S; Sinangil F; Steimer K; Walker M C; Wassef N; Xu S
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines.
The Journal of infectious diseases 1997;175(4):764-74.
1996: Gorse G J; Yang E Y; Belshe R B; Berman P W
Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group.
Clinical and diagnostic laboratory immunology 1996;3(6):769-73.
1996: Gorse G J; Patel G B; Newman F K; Belshe R B; Berman P W; Gregory T J; Matthews T J
Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.
Clinical and diagnostic laboratory immunology 1996;3(4):378-86.
1996: Kemp E B; Belshe R B; Hoft D F
Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin.
The Journal of infectious diseases 1996;174(1):113-9.
1996: Treanor J J; Betts R F; Smith G E; Anderson E L; Hackett C S; Wilkinson B E; Belshe R B; Powers D C
Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.
The Journal of infectious diseases 1996;173(6):1467-70.
1996: Gruber W C; Belshe R B; King J C; Treanor J J; Piedra P A; Wright P F; Reed G W; Anderson E; Newman F
Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group.
The Journal of infectious diseases 1996;173(6):1313-9.
1996: Mascola J R; Snyder S W; Weislow O S; Belay S M; Belshe R B; Schwartz D H; Clements M L; Dolin R; Graham B S; Gorse G J; Keefer M C; McElrath M J; Walker M C; Wagner K F; McNeil J G; McCutchan F E; Burke D S
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1996;173(2):340-8.
1996: Gorse G J; Keefer M C; Belshe R B; Matthews T J; Forrest B D; Hsieh R H; Koff W C; Hanson C V; Dolin R; Weinhold K J; Frey S E; Ketter N; Fast P E
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1996;173(2):330-9.
1995: Belshe R B
A review of attenuation of influenza viruses by genetic manipulation.
American journal of respiratory and critical care medicine 1995;152(4 Pt 2):S72-5.
1995: Gorse G J; Patel G B; Newman F K; Mandava M; Belshe R B
Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1995;13(13):1170-9.
1995: Lagging L M; Meyer K; Hoft D; Houghton M; Belshe R B; Ray R
Immune responses to plasmid DNA encoding the hepatitis C virus core protein.
Journal of virology 1995;69(9):5859-63.
1995: Powers D C; Smith G E; Anderson E L; Kennedy D J; Hackett C S; Wilkinson B E; Volvovitz F; Belshe R B; Treanor J J
Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults.
The Journal of infectious diseases 1995;171(6):1595-9.
1995: Ray R; Meyer K; Newman F K; Belshe R B
Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain.
Journal of virology 1995;69(3):1959-63.
1995: Gorse G J; Rogers J H; Perry J E; Newman F K; Frey S E; Patel G B; Belshe R B
HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1995;13(2):209-14.
1994: Keefer M C; Graham B S; Belshe R B; Schwartz D; Corey L; Bolognesi D P; Stablein D M; Montefiori D C; McElrath M J; Clements M L
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
AIDS research and human retroviruses 1994;10(12):1713-23.
1994: Gorse G J; Schwartz D H; Graham B S; Matthews T J; Stablein D M; Frey S E; Belshe R B; Clements M L; Wright P F; Eibl M
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.
Clinical and experimental immunology 1994;98(2):178-84.
1994: Belshe R B; Clements M L; Keefer M C; Graham B S; Corey L; Sposto R; Wescott S; Lawrence D
Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group.
Annals of internal medicine 1994;121(8):584-9.
1994: Graham B S; Gorse G J; Schwartz D H; Keefer M C; McElrath M J; Matthews T J; Wright P F; Belshe R B; Clements M L; Dolin R
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
The Journal of infectious diseases 1994;170(4):782-6.
1994: Anderson E L; Bowers T; Mink C M; Kennedy D J; Belshe R B; Harakeh H; Pais L; Holder P; Carlone G M
Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.
Infection and immunity 1994;62(8):3391-5.
1994: Gorse G J; Frey S E; Patel G; Newman F K; Belshe R B
Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1994;12(10):912-8.
1994: Belshe R B; Graham B S; Keefer M C; Gorse G J; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi D P; Sposto R
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
JAMA : the journal of the American Medical Association 1994;272(6):475-80.
1994: Westblom T U; Gudipati S; DeRousse C; Midkiff B R; Belshe R B
Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule.
The Journal of infectious diseases 1994;169(5):996-1001.
1994: Powers D C; Belshe R B
Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin".
The Journal of infectious diseases 1994;169(5):1125-9.
1994: Swierkosz E M; Newman F K; Anderson E L; Nugent S L; Mills G B; Belshe R B
Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children.
The Journal of infectious diseases 1994;169(5):1121-4.
1994: Karron R A; Froehlich J L; Bobo L; Belshe R B; Yolken R H
Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: use of reverse transcription-PCR-enzyme immunoassay.
Journal of clinical microbiology 1994;32(2):484-8.
1994: Anderson E L; Mink C M; Berlin B S; Shih C N; Tung F F; Belshe R B
Acellular pertussis vaccines in infants: evaluation of single component and two-component products.
Vaccine 1994;12(1):28-31.
1994: Keefer M C; Belshe R; Graham B; McElrath J; Clements M L; Sposto R; Fast P
Safety profile of HIV vaccination: first 1000 volunteers of AIDS vaccine evaluation group. NIAID AIDS Vaccine Clinical Trials Network.
AIDS research and human retroviruses 1994;10 Suppl 2():S139-40.
1993: Belshe R B; Clements M L; Dolin R; Graham B S; McElrath J; Gorse G J; Schwartz D; Keefer M C; Wright P; Corey L
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
The Journal of infectious diseases 1993;168(6):1387-95.
1993: Anderson E L; Becherer P R; Belshe R B
Revaccination with pneumococcal and hepatitis B vaccines.
JAMA : the journal of the American Medical Association 1993;270(22):2735-6.
1993: Belshe R B; Anderson E L; Walsh E E
Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children.
The Journal of infectious diseases 1993;168(4):1024-9.
1993: Schwartz D H; Gorse G; Clements M L; Belshe R; Izu A; Duliege A M; Berman P; Twaddell T; Stablein D; Sposto R
Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.
Lancet 1993;342(8863):69-73.
1993: Powers D C; Belshe R B
Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine.
The Journal of infectious diseases 1993;167(3):584-92.
1993: Graham B S; Matthews T J; Belshe R B; Clements M L; Dolin R; Wright P F; Gorse G J; Schwartz D H; Keefer M C; Bolognesi D P
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
The Journal of infectious diseases 1993;167(3):533-7.
1992: Gorse G J; Frey S E; Newman F K; Belshe R B
Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
Journal of clinical microbiology 1992;30(10):2606-12.
1992: Anderson E L; Newman F K; Maassab H F; Belshe R B
Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children.
Journal of clinical microbiology 1992;30(9):2230-4.
1992: Graham B S; Belshe R B; Clements M L; Dolin R; Corey L; Wright P F; Gorse G J; Midthun K; Keefer M C; Roberts N J
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.
The Journal of infectious diseases 1992;166(2):244-52.
1992: Belshe R B; Karron R A; Newman F K; Anderson E L; Nugent S L; Steinhoff M; Clements M L; Wilson M H; Hall S L; Tierney E L
Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children.
Journal of clinical microbiology 1992;30(8):2064-70.
1992: Belshe R B; Swierkosz E M; Anderson E L; Newman F K; Nugent S L; Maassab H F
Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine.
The Journal of infectious diseases 1992;165(4):727-32.
1992: Hall S L; Stokes A; Tierney E L; London W T; Belshe R B; Newman F C; Murphy B R
Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys.
Virus research 1992;22(3):173-84.
1992: Gorse G J; Belshe R B; Newman F K; Frey S E
Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1992;10(6):383-8.
1991: Clements M L; Belshe R B; King J; Newman F; Westblom T U; Tierney E L; London W T; Murphy B R
Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.
Journal of clinical microbiology 1991;29(6):1175-82.
1991: Dolin R; Graham B S; Greenberg S B; Tacket C O; Belshe R B; Midthun K; Clements M L; Gorse G J; Horgan B W; Atmar R L
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
Annals of internal medicine 1991;114(2):119-27.
1988: Halsey N A; Anderson E L; Sears S D; Steinhoff M; Wilson M; Belshe R B; Midthun K; Kapikian A Z; Chanock R M; Samorodin R
Human-rhesus reassortant rotavirus vaccines: safety and immunogenicity in adults, infants, and children.
The Journal of infectious diseases 1988;158(6):1261-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Robert Belshe

Research Profile (preview)

Chemicals & Drugs

Procedures

Living Beings

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Robert Belshe (preview)

All Publications